Technology Innovator Awards 2020

Jun20084 Leading Pioneers in Tissue & Organ Printing Technology 2020 regenHU is a pioneer and global leader in tissue and organ printing technologies converging digital manufacturing (3D printing), biomaterials and biotechnology to lead transformational innovations in healthcare. Recently, we profiled the regenHU to discover more about the firm and how they established a reputation as one of leading pioneers in tissue and organ printing technology. Founded in 2007, regenHU was established to innovate and grow the technology of 3Dbioprinting from its earliest days, in which the potential of the technology to alter many areas of health care being clearly understood by the founders. Today, the global leader designs, develops andmanufactures bioprinting instruments, bioprinting software, and solutions for transformational innovation in tissue engineering, regenerative medicine and drug discovery, with precision and reproducibility in mind, for today’s researchers and tomorrows industrial biofabrication needs. By personalizing each instrument to the specific project needs of the users, the team at regenHU provide multiple bioprinting technologies in one instrument, enabling true multi-material printing for their global customer portfolio comprising key players in biotech, pharma, cosmetics, and MedTech industries in addition to leading universities around the world. The instruments regenHU develops, offer a unique solution to their customers, through a carefully blended combination of personalization of the bioprinter, from a vast range of various print technologies on the one instrument. Combining this with the high quality precision robotic systems, regenHU’s instruments offer printing technology convergence with robust and repeatable performance, which in turn enables today’s researchers to explore new medical applications in addition to the potential of fabricating products to scale. For regenHU, their main mission is to evolve bioprinting by pushing technology boundaries to the point where using bioprinters for industrial scale medical product manufacture is a reality. However, one of the key challenges they face is the current limitations in the scale and volume of bioprinting, which is linked to the reproducibility of the print. To progress into the manufacture of medical products, bioprinters will need to operate at a scale beyond current capabilities. With this in mind, regenHU design their instruments and have assembled a team with the specific aim to solve the many challenges in achieving this. Supporting founder of regenHU, Simon MacKenzie om his mission to evolve bioprinting, is the motivated and driven team that he, as he states, is so fortunate to work alongside. Simon’s primary role is to provide the right support structure to enable their entrepreneurial engineering team to thrive and be brave enough to push boundaries. In addition to this, Simon works hard to establish an environment that grants the team the freedom to develop technologies that they passionately believe will change the way in which they find medicines and treat disease. Having established a reputation for being pioneers in 3Dbioprinting, and from working closely with their user community, regenHU have clearly seen the limitations have been preventing them reaching the commercial biofabrication of tissues and organs. Going forward, the team’s motivation comes from developing solutions to these problems, which they will continue to bring to the market for the next few years. Organtrans, a European consortium that regenHU is a part of, is a good example of the solution driven projects the firm are currently engaged in and that will move the field closer to the potential of true regenerative medicine. As a long established member of the bioprinting community, regenHU have active interest in advancing the field towards therapeutic and regenerative strategies. Over the past few years, the development of the company had reached a plateau, whilst a range of technology challenges were being tackled. Having now developed solutions to help them get to their ideal position, regenHU is going through an significant evolution of structure, goals and the technologies we create, to enable us to achieve the next stage of our ambitious plan to revolutionize tissue engineering. Contact: Simon MacKenzie Company: regenHU Ltd Address: Z.I. du Vivier, 1690 Villaz-St-Pierre, Switzerland Telephone: +41 26 653 7220 Web Address: www.regenhu.com